Equillium (EQ) EBT Margin (2023 - 2024)
Equillium (EQ) posted quarterly EBT Margin of 123.7% for Q4 2024, down 9845.0% year-over-year from 1.27% in Q1 2024, and down 214806.04% quarter-over-quarter from 0.06% in Q3 2024.
Equillium (EQ) EBT Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported EBT Margin for 2 consecutive years, with 123.7% the latest figure, recorded in Q4 2024.
- In Q4 2024, EBT Margin fell 9845.0% year-over-year to 123.7%; the TTM figure through Sep 2025 stood at 661.57% (down 65155.0% YoY), while the FY2024 annual figure was 18.75%, up 1660.0% from the prior year.
- EBT Margin retreated to 123.7% in Q4 2024 per EQ's latest filing, from 0.06% in the prior quarter.
- Across five years, EBT Margin topped out at 3.38% in Q2 2024 and bottomed at 123.7% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -123.70% |
| Sep 30, 2024 | -0.06% |
| Jun 30, 2024 | 3.38% |
| Mar 31, 2024 | -25.58% |
| Dec 31, 2023 | -25.25% |
| Sep 30, 2023 | -36.23% |
| Jun 30, 2023 | -36.55% |
| Mar 31, 2023 | -43.70% |